Tonix Pharmaceuticals to Present at ACR Convergence 2024
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a dynamic biopharmaceutical firm focused on innovative solutions in pain management and public health, is excited to announce that its Chief Executive Officer, Seth Lederman, M.D., will present a poster at the upcoming ACR Convergence 2024 Annual Meeting. This annual event is a cornerstone for rheumatology professionals, scheduled to take place in Washington, D.C., attracting researchers and clinicians from around the globe.
Presentation Highlights
The poster presentation will detail the findings from a significant clinical trial focusing on fibromyalgia treatment. Dr. Lederman's presentation is set for a prominent slot in Poster Session B, which will feature innovative research on pain in rheumatic diseases, including fibromyalgia. Attendees can expect to gain insights into the randomized, double-blind, placebo-controlled confirmatory Phase 3 Trial of TNX-102 SL, a unique sublingual formulation of cyclobenzaprine.
Key Presentation Details
Here are some essential details about the presentation that attendees should note:
- Presenter: Seth Lederman, M.D.
- Title: Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
- Poster No.: 1218
- Session: Poster Session B, Pain in Rheumatic Disease Including Fibromyalgia Poster
- Location: Walter E. Washington Convention Center
- Date: Sunday, November 17, 2024
- Time: 10:30 a.m. – 12:30 p.m. ET
About TNX-102 SL and Its Importance
Tonix's leading product candidate, TNX-102 SL, is designed specifically for fibromyalgia management. The clinical results demonstrated statistically significant outcomes, prompting Tonix to submit a New Drug Application (NDA) to the FDA, which has already granted it Fast Track designation. This expedited path underscores the medicine's potential to transform care for patients suffering from chronic pain disorders.
TNX-102 SL does not only aim at fibromyalgia but also has therapeutic applications for acute stress reaction and acute stress disorder. Research surrounding these applications continues, backed by initiatives at esteemed institutions including the University of North Carolina.
Broader Portfolio of Innovations
Tonix Pharmaceuticals isn't stopping at fibromyalgia; its development portfolio encompasses a range of treatments addressing various central nervous system (CNS) disorders. Among its pipeline, TNX-1300 is being advanced for cocaine intoxication, having received FDA Breakthrough Therapy designation, positioning Tonix as a leader in developing critical therapies.
Commitment to Public Health
Tonix's innovations also extend into immunology, where it seeks to address challenges like organ transplant rejection and autoimmune diseases. The development of TNX-1500, a monoclonal antibody targeting CD40-ligand, represents a proactive step towards enhancing patient outcomes in transplant scenarios.
Contracts and Collaborations
In a recent development, Tonix secured a contract with the U.S. Department of Defense’s Defense Threat Reduction Agency to develop TNX-4200, broad-spectrum antiviral agents. This contract, which could be valued at up to $34 million over five years, showcases Tonix’s commitment to addressing urgent health concerns and improving the medical readiness of military personnel.
Contact Information
For those interested in further details about Tonix Pharmaceuticals and its groundbreaking projects, please reach out to:
Investor Contact:
Jessica Morris
(862) 904-8182
investor.relations@tonixpharma.com
Media Contact:
Ray Jordan
(949) 245-5432
ray@putnaminsights.com
Frequently Asked Questions
What is Tonix Pharmaceuticals presenting at ACR 2024?
Tonix Pharmaceuticals will present findings from a Phase 3 Trial on TNX-102 SL, focusing on fibromyalgia treatment.
Who is the presenter at the ACR conference?
The presentation will be delivered by Seth Lederman, M.D., the CEO of Tonix Pharmaceuticals.
When and where will the presentation take place?
The poster presentation is scheduled for November 17, 2024, in Washington, D.C., at the Walter E. Washington Convention Center.
What is TNX-102 SL?
TNX-102 SL is a sublingual formulation of cyclobenzaprine aimed at providing relief for individuals suffering from fibromyalgia.
What other products are in Tonix's pipeline?
Tonix's pipeline includes treatments for cocaine intoxication, organ transplant rejection, and a vaccine for mpox among others, emphasizing its commitment to diverse health challenges.
